IRVINE, Calif., December 1, 2025 – Knobbe Martens is pleased to share that the firm was recognized among the best performing and most active Hatch-Waxman litigation firms in Patexia’s 2025 ANDA Litigation Intelligence Report. The report offers a comprehensive view of Hatch-Waxman litigation over the past five years and provides rankings of the most active stakeholders in Hatch-Waxman litigation.
Knobbe Martens ranked highly across multiple categories in the report, including among:
- The best performing law firms representing defendants in Hatch-Waxman litigation
- The best performing law firms in Hatch-Waxman litigation overall
- The most active law firms representing defendants in Hatch-Waxman litigation
More information on Patexia’s 2025 ANDA Litigation Intelligence Report can be found here.
Knobbe Martens’ Hatch-Waxman litigation team is recognized throughout the industry for representing leading generic pharmaceutical companies in high-stakes litigation. Earlier this year, the firm secured a significant victory for Padagis Pharmaceuticals in long-running litigation involving a generic version of the glaucoma medication Simbrinza®. The firm also prevailed on behalf of Lupin in a complex, long-standing Hatch-Waxman dispute concerning a critical medication used to treat life-threatening kidney disease.
Learn more about Knobbe Martens’ Hatch-Waxman Litigation practice here.
Subscribe for News and Updates